Nahar, Vinayak K. http://orcid.org/0000-0002-6771-1662
Wilkerson, Amanda H.
Pearlman, Ross L.
Ferris, Taylor S.
Zardoost, Pooya
Payson, Shirley N.
Aman, Iram
Quadri, Syed Siraj A.
Brodell, Robert T.
Article History
Received: 7 January 2020
Revised: 17 January 2020
Accepted: 25 January 2020
First Online: 13 February 2020
Conflict of interest
: Robert Brodell, MD, FAAD has the following conflicts of interest: multicenter clinical trials: Novartis—principal investigator; Corrona Psoriasis Biologic Registry. Editorial boards: Faculty Advisor, American Medical Student Research Journal; Editor-in-Chief, Practice Update Dermatology; Associate Editor, Journal of the American Academy of Dermatology; Practical Dermatology; Journal of the Mississippi State Medical Society; SKIN: The Journal of Cutaneous Medicine; Archives of Dermatological Research. Advisory boards: Bracco Diagnostics, Inc. (gadolinium-based contrast agent litigation); Chairperson of REGN3500 AD independent monitoring committee (iDMC) (Sanofi Genzyme/Regeneron); SunPharma; and Cassiopea. There are no conflicts of interest related to employment, stock ownership, expert testimony, grants, patents filed, received, pending, or in preparation, or royalties. Vinayak K. Nahar, MD, PhD, Amanda H. Wilkerson, PhD, Ross L. Pearlman, MD, Taylor S. Ferris, BA, Pooya Zardoost, MS, Shirley N. Payson, MS, Iram Aman, MD, and Syed Siraj A. Quadri, PhD, have no conflicts of interest.